Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

v3.23.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Option Activities
Following is a summary of stock option activities for the nine months ended September 30, 2023:
Options Weighted
Average
Exercise Price
Weighted
Average
Grant Date
Fair Value
Weighted
Average
Remaining
Life
(years)
Intrinsic
Value
Outstanding – January 1, 2023 7,603,864  $ 0.19  $ 0.21  4.6 $ 25,795 
Granted —  —  — 
Exercised (348,013) 0.18  0.23 
Forfeited —  —  — 
Outstanding – September 30, 2023
 7,255,851  $ 0.19  $ 0.21  3.8 $ 17,429 
Exercisable as of September 30, 2023
 7,255,851  $ 0.19  $ 0.21  3.8 $ 17,429 
Summary of Restricted Stock Activity

Restricted Stock Units
Weighted Average Grant Date
Fair Value
Non-vested – January 1, 2023 7,466,636  $ 5.52 
Granted
 675,293  3.55 
Vested
 (1,830,986) 6.31 
Forfeited
 (202,145) 6.03 
Non-vested – September 30, 2023
 6,108,798  $ 5.05 
Summary of Stock-based Compensation Expense
Stock-based compensation expense for stock options and restricted stock units in the unaudited interim condensed consolidated statements of operations is summarized as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
2023 2022 2023 2022
Software development
 $ 147  $ 189  $ 608  $ 718 
General and administrative(1)
 2,903  1,439  7,915  4,657 
Selling and marketing
 280  57 486  252
Total stock-based compensation expense
 $ 3,330  $ 1,685  $ 9,009  $ 5,627 
________
(1) For the nine months ended September 30, 2023, the Company included a credit of $339 in connection with the settlement of the equity-based portion of contingent consideration related to the acquisition of Trinity Air Medical, Inc. that was paid in the first quarter of 2023 in respect of 2022 results.